Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this analysis, safety data from two clinical trials showed that baricitinib for severe alopecia areata had predictable side effects like infections and elevated CPK, with some serious adverse events noted at low incidence rates; no deaths were reported.

This abstract contains no research results; it provides information about the JAMA Dermatology journal and its access options.

This study observed significant repigmentation in localized stable vitiligo lesions treated with oral baricitinib, with even more improvement when combined with topical tacrolimus, and reported no side effects.

This study describes the successful management of Andean bear alopecia syndrome in three female bears using oclacitinib, leading to rapid pruritus resolution and fur regrowth without adverse effects.

This abstract provides an overview of various topics related to pharmaceutical and therapeutic interventions, including acyclovir and photodynamic therapy for alopecia, but does not report new research findings.

This study found that topical calcipotriol lotion resulted in hair regrowth in 59.1% of alopecia areata patients, with better response observed in those with lower serum vitamin D levels.

This study found that antiandrogenic therapy with Melleva 35 for three months was effective in reducing hair loss and improving acne in women with both Androgenetic Alopecia and Acne Vulgaris.

This study concluded that removing alopecia and mucous membrane components from the CLASI-A score limits the ability to capture crucial clinical information about cutaneous lupus erythematosus activity, recommending their retention.

Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.

This review details how baricitinib successfully demonstrated significant hair regrowth in clinical trials for severe alopecia areata, now leading to its approval as the first systemic therapy for the condition, while also highlighting the importance of assessing individual risk factors for adverse events.

Baricitinib helps keep hair, eyebrows, and eyelashes regrown for 3 years in most people with severe hair loss.

This study found that topical calcipotriol may safely and effectively treat mild-to-moderate patchy alopecia areata, with significant hair regrowth observed in the majority of participants over 12 weeks.

In a retrospective clinical study, this research found that baricitinib is effective for alopecia areata, with 42.3% of patients achieving a significant reduction in hair loss by week 36, and 52.4% by week 52, outperforming previous trials.

Acitretin significantly reduced inflammatory attacks in a woman with Naevus Comedonicus Syndrome but caused side effects.

This study reports that baricitinib was more effective than placebo in promoting hair growth in adults with severe alopecia areata after 36 weeks of treatment in clinical trials.

This study conducted at Baghdad Teaching Hospital found that topical applications of Ciprofloxacin and Clindamycin effectively reduced acne severity indices in patients with mild to moderate acne vulgaris over 12 weeks, with Ciprofloxacin showing a greater reduction in papules and pustules compared to Clindamycin.

In this case report, etanercept was observed to effectively resolve symptoms of refractory acrodermatitis continua suppurativa Hallopeau after previous treatments had limited success.

Oral retinoids are effective for severe skin conditions but require careful use due to side effects.

In this clinical trial, adding topical calcipotriol to intralesional triamcinolone acetonide significantly increased hair regrowth efficacy in scalp alopecia areata patches compared to steroids alone, but not in beard patches, with a lower incidence of atrophy observed.

This article highlights the benefits of combining calcipotriene and betamethasone for treating localized plaque-type, scalp, and nail psoriasis, enhancing effectiveness while reducing side effects compared to single-agent therapies.

The authors report that a 62-year-old woman with invasive conjunctival squamous cell carcinoma experienced complete remission two years after combining cemiplimab, retinoic acid, and IFNα-2b treatments, highlighting potential utility despite limited availability of IFNα-2b.

This case report describes a 7-year-old boy with alopecia areata and reduced vitamin D receptor expression whose condition improved after using calcipotriol, a strong vitamin D analog.

Tofacitinib may effectively treat folliculitis decalvans.

Reflectance confocal microscopy is a useful, non-invasive tool for diagnosing some skin diseases, with potential for future improvements.

This study found that in noise-exposed FVB/NJ mice and cell models, ivacaftor reduced oxidative stress and hearing damage by maintaining CFTR function and increasing Nrf2 expression, suggesting its potential for treating noise-induced hearing loss.

This study investigates whether adding 30% supramolecular salicylic acid to conventional treatment for mild to moderate acne vulgaris is safe and effective, though specific results are not reported in the abstract.

This study found that vismodegib was effective in treating basal cell carcinoma, achieving complete remission in some patients; however, significant side effects often required careful management to prevent therapy suspension, which can lead to resistance.

In this study, baricitinib for severe alopecia areata showed sustained efficacy over 104 weeks, with most Week-52 responders maintaining significant hair regrowth and some mixed responders improving further with long-term treatment.

In this case report, a combination treatment of intralesional triamcinolone acetonide, oral acitretin, and topical clobetasol propionate showed effectiveness in reducing symptoms of Graham-Little-Piccardi-Lasseur syndrome in one patient over two months, with no new areas of hair loss observed.